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A rise in the incidence of bullous pemphigoid (BP) was documented recently in Europe, and the main risk
factors for BP remain unknown. We conducted a multicenter case–control study to evaluate risk factors for BP.
We identified 201 incident BP cases and 345 controls individually matched for age, gender, center, and place of
residence (home, nursing home, or extended-care facility). We used univariate and multivariate logistic
regression analyses to compare drugs used for over 3 months, comorbidities, and physical and cognitive
impairments between cases and controls. Mean age of BP patients was 84.2 (±8.7) years. Factors independently
associated with BP by multivariate analysis were major cognitive impairment (odds ratio (OR), 2.19; 95%
confidence interval (95% CI), 1.24–3.87), bedridden condition (OR, 2.19; 95% CI, 1.23–3.89), Parkinson’s disease
(OR, 2.16; 95% CI, 1.09–4.27), unipolar or bipolar disorder (OR, 5.25; 95% CI, 1.21–22.86), and chronic use of
spironolactone (OR, 2.30; 95% CI, 1.20–4.46) or phenothiazines with aliphatic side chains (OR, 3.70; 95% CI,
1.21–11.34). Chronic analgesic use was associated with a lower risk of BP (OR, 0.49; 95% CI, 0.30–0.81). Thus, risk
factors for BP include neurological disorders, particularly dementia and Parkinson’s disease, psychiatric
disorders (unipolar and bipolar disorders), bedridden condition, and chronic use of several drugs.
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INTRODUCTION
Bullous pemphigoid (BP) is the most common subepidermal
autoimmune bullous disease (Bernard et al., 1995; Zillikens
et al., 1995). A recent study conducted in the United
Kingdom found an incidence of 4.3 (95% confidence interval
(95% CI), 4.0–4.6) per 100,000 person-years (Langan et al.,
2008). BP mainly affects elderly patients. Thus, the incidence
of BP increases significantly after the age of 60 years (Bernard
et al., 1995; Jung et al., 1999; Langan et al., 2008), and the
mean age of European patients with BP ranged in recent
studies from 77 to 83 years (Joly et al., 2002, 2005; Cordel
et al., 2007; Joly et al., 2009). The recent increase in BP
incidence affects all age groups (Langan et al., 2008) and,
consequently, cannot be ascribed to aging of the population.
The causes of the increase are unknown, and neither is the
predilection of BP for older patients understood.
Several studies have suggested risk factors for BP.
A prospective multicenter case–control study indicated that
chronic intake of neuroleptics and aldosterone antagonists
increased the risk of BP (Bastuji-Garin et al., 1996).
A retrospective study showed an increased prevalence of
diabetes among BP patients (Chuang et al., 1984), and an
association was reported between BP and psoriasis (Grattan,
1985). Moreover, several neurological disorders were
common in BP patients in case reports (Masouye´ et al.,
1989; Kirtschig et al., 1995; Chosidow et al., 2000; Stinco
et al., 2002) and in a retrospective case–control study
(Foureur et al., 2001). Finally, another study found that
one-third of 341 BP patients had one of three severely
disabling neurological disorders, namely, dementia, stroke,
and Parkinson’s disease (Cordel et al., 2007), and that BP
patients with neurological diseases had lower Karnofsky
scores and worse functional impairment than those without
neurological diseases (Cordel et al., 2007). Many cases of
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localized BP have been reported in patients with hemiplegia
(Long et al., 1992; Bunker and Brown, 1993; Foureur et al.,
2001), suggesting that immobility, muscle weakness, or
dependency may have a role in the pathogenesis of BP
lesions.
The objective of this study was to identify risk factors for
BP. We directed special attention to assessing the influence of
chronic drug intake and of the above-mentioned neurological
conditions. This was a large multicenter hospital-based
case–control study in 11 dermatology departments in France.
RESULTS
Patients
The 201 cases had a mean age of 82.4 (8.7) years; 130
(64.7%) were females and 71 were males. Median number of
new blisters per day was 20 (interquartile range (IQR), 9–32).
Median peripheral eosinophil count was 847 giga cells per
liter (IQR, 400–1780). Control patients were well matched on
cases for age (P¼ 0.77), gender (P¼ 0.38), center (P¼0.90),
and place of residence (P¼0.38) (Table 1).
Univariate analysis
The univariate analysis (Table 1) showed that the cases were
significantly more disabled than the controls. Thus, the cases
had higher rates of major cognitive impairment (mini-mental
state examination (MMSE) p17; odds ratio (OR), 3.57; 95%
CI, 2.27–5.62) and dependency (Barthel index o20; OR,
3.61; 95% CI, 2.24–5.82), and were more frequently confined
to bed (Braden scale score o17, indicating a high risk of
pressure sores; OR, 3.17; 95% CI, 2.05–4.89). Cases had
significantly higher rates of stroke (OR, 2.02; 95% CI,
1.27–3.23), Parkinson’s disease (OR, 2.71; 95% CI,
1.48–4.97), and unipolar or bipolar disorder (OR, 3.37;
95% CI, 0.99–11.44). Multiple sclerosis was present in one
case and no controls. No association was found between BP
and diabetes (P¼ 0.56), thyroid dysfunction (P¼0.88), a
history of chronic wounds (P¼0.30), or other dermatological
conditions such as psoriasis (P¼0.80) (data not shown).
Chronic intake of at least one drug before BP onset was
noted in 183 (91.0%) cases. Among the controls, 310 (89.9%)
received chronic treatment with at least one drug. Mean
Table 1. Univariate comparison of cases and controls
Cases (n=201) Controls (n=345) OR (95% CI)1 P-value2
Matching variables
Mean (±1 SD) age, years 82.4±8.7 82.2±8.6 — 0.77
Female/male ratio 1.8/1 1.6/1 — 0.38
Place of residence, n (%)
Home 128 (66.0) 236 (70.2) — —
Nursing home 60 (29.9) 94 (27.3) — —
Extended-care geriatric facility 13 (6.7) 15 (4.5) — 0.22
BMI, median (IQR) 24 (21–28) 25 (21.5–27) — 0.29
Braden scale score, median (IQR)3 19 (14–23) 22 (18.23) — o0.001
Braden scale score o17, n (%) 77 (38.5) 61 (17.9) 3.17 (2.05–4.89) o0.001
Barthel index, median (IQR)4 53 (10–100) 95 (55–100) o0.001
Barthel index o204 60 (30.0) 38 (11.2) 3.61 (2.24–5.82) o0.001
Comorbidities, n (%)
Severe cognitive impairment (MMSE p17)5 82 (42.7) 69 (20.9) 3.57 (2.27–5.62) o0.001
Stroke 45 (25.9) 46 (14.8) 2.02 (1.27–3.23) 0.003
Parkinson’s disease 28 (14.3) 20 (5.8) 2.71 (1.48–4.97) 0.001
Unipolar and bipolar disorders 8 (4.0) 4 (1.2) 3.37 (0.99–11.44) 0.051
Diabetes 12 (6.0) 16 (4.6) 1.26 (0.58–2.74) 0.56
Psoriasis 9 (4.5) 12 (3.5) 1.30 (0.44–2.0) 0.65
Past fracture or joint prosthesis 43 (21.7) 68 (20.2) 1.08 (0.69–1.68) 0.74
Abbreviations: BMI, body mass index; IQR, interquartile range; MMSE, mini-mental state examination; OR, odds ratio; 95% CI, 95% confidence interval.
1Odds ratios with 95% CIs were estimated using unconditional multiple logistic regression adjusted for matching variables (age, gender, center, and place of
residence).
2P-value of the w2-test, Fisher exact test, or nonparametric Kruskal–Wallis test, as appropriate.
3Braden scale score o17 indicates that the patient is confined to bed.
4Barthel index values o20 indicate dependency.
5Severe cognitive impairment was defined as a mini-mental state examination score no higher than 17.
P-values o0.15 (numbers in bold) were considered for the multivariate analyses.
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Table 2. Univariate comparison of drug intake in cases and controls
Cases (n=201),
number (%)
Controls (n=345),
number (%) OR (95% CI)1 P–value2
Diuretics 73 (36.3) 111 (32.2) 1.22 (0.84–1.76) 0.32
Spironolactone 26 (12.9) 26 (7.4) 1.90 (1.06–3.40) 0.03
Benzothiadiazides 20 (10.0) 42 (12.2) 0.81 (0.46–1.44) 0.47
Furosemide 49 (24.4) 73 (21.2) 1.21 (0.79–1.84) 0.38
Other cardiovascular drugs
Amiodarone 13 (6.5) 22 (6.4) 1.03 (0.50–2.09) 0.94
b-Blockers 39 (19.4) 67 (19.4) 1.03 (0.66–1.60) 0.91
Angiotensin-converting enzyme inhibitors 57 (28.4) 113 (32.8) 0.83 (0.56–1.21) 0.33
Angiotensin II receptor antagonists 16 (8.0) 25 (7.3) 1.12. (0.58–2.16) 0.73
Calcium channel blockers 40 (19.9) 81 (23.5) 0.83 ((0.54–1.27) 0.39
Central antihypertensive drugs 11 (5.5) 14 (4.1) 1.42 (0.63–3.20) 0.40
Vasodilators 37 (18.4) 70 (20.3) 0.95 (0.58–1.12) 0.56
Lipid-lowering drugs 29 (14.4) 79 (22.9) 0.56 (0.35-.92) 0.02
Statins 23 (11.4) 57 (16.5) 0.66 (0.39–1.12) 0.10
Fenofibrates 6 (3.0) 22 (6.4) 0.45 (0.18–1.15) 0.095
Psycholeptics (NO5) 106 (52.7) 119 (34.5) 2.11 (1.46–3.04) o0.001
Antipsychotic drugs (NO5A) 24 (11.9) 29 (8.4) 1.60 (0.89–2.75) 0.16
Phenothiazine aliphatic chain (NO5AA) 13 (6.5) 7 (2.3) 3.29 (1.29–8.41) 0.013
Anxiolytics (NO5B) 50 (24.9) 72 (20.9) 1.40 (0.88–2.0) 0.28
Benzodiazepine derivatives (NO5BA) 40 (19.9) 55 (15.9) 1.28 (0.81–2.02) 0.29
Diphenylmethane derivatives (NO5BB) 13 (6.5) 14 (4.1) 1.75 (0.82–3.41) 0.18
Carbamates (NO5BC) 7 (3.5) 8 (2.3) 1.35 (0.50–4.00) 0.49
Hypnotics and sedatives (NO5C) 30 (14.9) 44 (12.8) 1.16 (0.70–1.92) 0.57
Antiparkinson drugs 21 (10.5) 15 (4.4) 2.54 (1.26–5.12) 0.009
Anticholinergic drugs 2 (1.0) 0 —
Dopaminergic drugs 19 (9.5) 15 (4.4) 2.28 (1.12–4.65) 0.02
Corticosteroids 15 (7.5) 33 (9.6) 0.76 (0.40–1.44) 0.40
NSAIDs 8 (4.0) 16 (4.6) 0.84 (0.35–2.02) 0.70
Analgesics 34 (16.9) 102 (29.6) 0.48 (0.31–0.74) 0.001
Opioids 19 (9.5) 57 (16.5) 0.50 (0.29–0.88) 0.02
Salicylates 19 (9.5) 52 (15.1) 0.55 (0.31–0.97) 0.04
Anilides (including acetaminophen) 18 (9.0) 47 (13.6) 0.58 (0.32–1.05) 0.07
Psychoanaleptics (NO6) 59 (29.4) 84 (24.4) 1.24 (0.83–1.85) 0.30
Antibiotics 17 (8.5) 20 (5.8) 1.52 (0.77–2.98) 0.23
Abbreviations: CI, confidence interval; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio.
1Odds ratios with CIs were estimated using unconditional multiple logistic regression adjusted for matching variables (age, gender, and place of residence).
2P-value of the w2-test, Fisher exact test, or nonparametric Kruskal–Wallis test, as appropriate.
P-values o0.15 (numbers in bold) were considered for the multivariate analyses.
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number of chronic drugs was 4.8 (3.1) in the cases and 4.9
(3.3) in the controls. BP was significantly associated with
chronic intake of spironolactone (OR, 1.90; 95% CI,
1.06–3.40), dopaminergic antiparkinson drugs (OR, 2.28;
95% CI, 1.12–4.65), and psycholeptic agents (OR, 2.11; 95%
CI, 1.46–3.04) (Table 2), most notably phenothiazine
psycholeptics with aliphatic side chains (OR, 3.29; 95% CI,
1.29–8.41). In contrast, a significantly larger proportion of
controls than of cases reported chronic intake of lipid-
lowering drugs (OR, 0.56; 95% CI, 0.35–0.92) and analgesics
(OR, 0.48; 95% CI, 0.31–0.74).
Mutivariate analysis
We found a strong association between the Braden score and
the Barthel index (Po0.0001), due to colinearity between these
two variables. Therefore, only the Braden score was used in the
multivariate analyses. A significant association between the
MMSE score and the Braden score was also evidenced
(Po0.01). In the bivariate analyses, no interaction was
observed and both variables remained significant. Stroke was
significantly associated (Po0.01) with the MMSE and Braden
scores; thus after adjusting for the MMSE and Braden scores, the
association between BP and stroke was no longer significant.
As the use of antiparkinson drugs was strongly associated with
Parkinson’s disease (Po0.0001), antiparkinson drug use was
not entered in the multivariate model. The following factors
were thus considered in the multivariate model: MMSE score,
Braden score, Parkinson’s disease, unipolar and bipolar
disorders, spironolactone, phenothiazine psycholeptics with
aliphatic side chains, lipid-lowering drugs, and analgesics. As
all analgesics associated with BP had similar ORs, analgesics
were pooled into a single group.
By multivariate analysis (Table 3), six factors were
significantly associated with BP: major cognitive impairment
(OR, 2.19; 95% CI, 1.24–3.87), Parkinson’s disease
(OR, 2.16; 95% CI, 1.09–4.27), bedridden condition (OR,
2.19; 95% CI, 1.23–3.89), unipolar or bipolar disorder
(OR, 5.25; 95% CI, 1.21–22.86), chronic use of spironolac-
tone (OR, 2.30 95% CI, 1.20–4.46), and chronic use of
phenothiazine psycholeptics with aliphatic side chains (OR,
3.70; 95% CI, 1.21–11.34). Chronic analgesic use was
significantly less common among cases (OR, 0.49; 95% CI,
0.30–0.81). The model had adequate discrimination and
calibration (Hosmer-Lemeshow statistic, 1.81 (nine degrees
of freedom); P¼0.98; area under the ROC curve, 0.71). The
prevalence rates of factors independently associated with
BP were similar across categories of controls, except
cognitive impairment and pressure sore risk, which were
higher among controls admitted for acute disorders. How-
ever, a multivariate analysis excluding these controls
produced similar results to those obtained using all the
controls (data not shown).
DISCUSSION
To our knowledge, this is the first prospective case–control
study assessing potential risk factors for BP, including drug
intake and comorbid conditions. The prospective design
allowed us to validate all BP diagnoses, to assess cognitive
function (MMSE), pressure sore risk (Braden scale), and self-
sufficiency (Barthel index), and to collect all chronic drugs.
Independent risk factors for BP were dementia, Parkinson’s
disease, unipolar or bipolar disorder, bedridden condition,
and chronic intake of spironolactone or psycholeptic agents.
These data confirm and extend those from our previous
studies on neurological disorders and chronic drug intake in
BP patients (Bastuji-Garin et al., 1996; Cordel et al., 2007) and
are in accordance with case-series studies and case reports
suggesting a relationship between BP and neurological
disorders (Masouye´ et al., 1989; Kirtschig et al., 1995;
Chosidow et al., 2000; Stinco et al., 2005; Cordel et al., 2007).
Both dementia and Parkinson’s disease were independent
risk factors for BP in our study. The rates of neurological
disorders among cases (42.7% for dementia and 14.3% for
Parkinson’s disease) were consistent with those found in a
retrospective study, in which 36% of BP patients had a
neurological disorder, 20% had dementia, and 9% had
Parkinson’s disease (Cordel et al., 2007). Dementia (MMSE
o17) was associated with a 2-fold increase in the risk of BP
compared with patients with higher MMSE scores. Functional
impairments were common among BP patients in previous
case-series studies from Europe (Joly et al., 2002, 2004, 2009;
Rzany et al., 2002; Cordel et al., 2007). Even after adjusting for
dementia and Parkinson’s disease, low Braden scale score
values were independent risk factors for BP in the multivariate
analysis; therefore, bedridden condition did not act only via an
association with disabling neurological diseases.
Several case reports and small case series have suggested
an association between BP and amyotrophic lateral sclerosis
(Chosidow et al., 2000), multiple sclerosis (Masouye´ et al.,
1989; Kirtschig et al., 1995; Stinco et al., 2002), hemiplegia
(Long et al., 1992; Bunker and Brown, 1993; Foureur et al.,
2001), and Shy–Drager syndrome (Okazaki et al., 1998).
Table 3. Relative risk estimates in multivariate
analysis comparing bullous pemphigoid cases (n=201)
to controls (n=345)
OR1 95% CI P-value
Severe cognitive impairment
(MMSE p17)
2.19 (1.24–3.87) 0.007
Bedridden condition (Braden scale
score o17)
2.19 (1.23–3.89) 0.008
Parkinson’s disease 2.16 (1.09–4.27) 0.03
Unipolar or bipolar disorder 5.25 (1.21–22.86) 0.027
Spironolactone 2.30 (1.20–4.46) 0.013
Phenothiazine aliphatic chain
(NO5AA)
3.70 (1.21–11.34) 0.022
Analgesics 0.49 (0.30–0.81) 0.006
Abbreviations: MMSE, mini-mental state examination; OR, odds ratio;
95% CI, 95% confidence interval.
1Odds ratios were adjusted for matching variables (age, gender, center,
and place of residence) and the variables listed in the table and were
estimated by unconditional multiple logistic regression.
Area under the receiving operating characteristic curve=0.71.
Goodness-of-fit test (Hosmer-Lemeshow w2-test (8))=1.81; P=0.98.
640 Journal of Investigative Dermatology (2011), Volume 131
S Bastuji-Garin et al.
Risk Factors for Bullous Pemphigoid
Only one of our BP patients had multiple sclerosis, possibly
because our population was composed chiefly of elderly
individuals, a population in which multiple sclerosis is rare.
A history of stroke was significantly associated with BP in
the univariate analysis, in keeping with earlier studies
(Long et al., 1992; Bunker and Brown, 1993; Foureur et al.,
2001; Cordel et al., 2007). However, no association between
BP and stroke was found in the multivariate analysis, because
stroke was closely linked to dependency (Braden scale score
o17) and dementia (MMSE p17) (Po0.01).
Thus, BP seems associated with degenerative neurological
diseases that may involve autoimmune mechanisms, such as
Parkinson’s disease and Alzheimer’s disease. Specific neuronal
antibodies have been found to accumulate within neurons in
Alzheimer’s disease and may initiate neuronal degeneration
(Bouras et al., 2005). Conceivably, an autoimmune response
initially directed against a neuronal isoform of BPAG1 (BPAG1-
n) encoded by the dystonin gene may secondarily trigger an
autoimmune response against the epithelial isoform of BPAG1,
according to the ‘‘epitope spreading’’ phenomenon (Fairley
et al., 2004). The two isoforms share the same sequence in their
terminal portion, which is recognized by anti-BPAG1 anti-
bodies from BP patients (Laffitte et al., 2005). Recombinant
BPAG1 fragments have been identified in cerebrospinal fluid
from patients with multiple sclerosis (Laffitte et al., 2005), and
serum from BP patients with neurological diseases recognized
BPAG1 in mouse skin and brain extracts (Li et al., 2009). The
rupture of tolerance induced by neuronal degeneration or
destruction of the brain parenchyma in some neurological
disorders may explain the delayed development of BP after the
onset of the neurological symptoms. The detection of anti-
BPAG2 antibodies in elderly patients with dementia and no
clinical manifestations of BP is also in accordance with this
hypothesis (Foureur et al., 2006).
Unipolar or bipolar disorder was an independent risk
factor for BP in our study. Although these disorders were
present in only eight cases and four controls, they remained
significant in the multivariate analysis after adjustment for
psycholeptic agent intake. To our knowledge, unipolar or
bipolar disorder has not been reported previously as a risk
factor for BP. The presence of unipolar or bipolar disorder
may be easier to determine in a prospective study than in a
retrospective study. This risk factor may have important
implications for the management of BP patients and deserves
to be further investigated.
In an earlier study, we found an association between BP
and drugs such as neuroleptics that might be related to
neurological diseases (Bastuji-Garin et al., 1996). Therefore,
in this study, we collected extensive information about drug
exposures, from the patients, family, nurses, and usual
physicians. Chronic spironolactone therapy was associated
with BP, with an OR of 2.30 (95% CI, 1.20–4.46), in keeping
with the results from our previous case–control study
(OR, 3.1; 95% CI, 1.3–7.1) (Bastuji-Garin et al., 1996).
Psycholeptic agents, chiefly neuroleptics, were indepen-
dently associated with BP in this study, indicating that their
influence was not mediated solely by an association with
dementia and/or unipolar or bipolar disorders. As expected,
antiparkinson drugs were strongly related to Parkinson’s
disease and were not significantly associated with BP in the
multivariate analysis. Finally, the lower rate of analgesic use
in BP cases compared with controls may be related to the
uncommon nature of pain complaints in patients with major
cognitive impairment who are confined to bed.
Our study has several limitations. Diagnostic bias is
unlikely, as the prospective design allowed us to confirm
all BP diagnoses based on clinical criteria (Vaillant et al.,
1998; Joly et al., 2004), histological criteria (Courville et al.,
2000), and immunological criteria (Joly et al., 1997) used in
many previous studies (Bastuji-Garin et al., 1996; Joly et al.,
2002, 2005, 2009; Bernard et al., 2009). The median number
of new blisters per day (20, IQR, 9–32) suggested that BP
severity in our study was similar to that previously reported in
France (Joly et al., 2002, 2009).
The hospital-based recruitment may have led to over-
representation of patients with severe BP and poor general
health. Population-based studies are theoretically less suscep-
tible to selection bias (Langan et al., 2008). However, in
population-based studies of BP involving direct validation of the
diagnosis, most patients had received their diagnosis in tertiary-
care centers. This study was conducted in France from 2003 to
2007, a period during which almost all BP patients were
referred to hospital dermatology departments for confirmation
of the diagnosis by direct immunofluorescence. The absence of
major selection bias in this study is also supported by the
similarities between mean age and main comorbidities in our
cases and in the BP patients in other European studies (Rzany
et al., 2002; Langan et al., 2008) or in the United States (Parker
et al., 2008). Finally, to take into account the poor general
health of a substantial proportion of BP patients (Joly et al.,
2002, 2009; Rzany et al., 2002), we individually matched each
case with two controls not only on age, gender, and center, but
also on place of residence (home, nursing home, or extended-
care geriatric facility). We cannot hypothesize that our controls
represent the general population, but the individual matching
for major confounding factors for diseases and medications
(age, gender, and place of residence) indicates that our
controls probably represented the population from which our
cases were taken. Furthermore, the prevalence of medication
with diuretics, b-blockers, and benzodiazepines in our patients
was similar to the prevalence reported among elderly patients
involved as controls in a previous study (Joly et al., 2007). Our
study was not blinded. However, a standardized questionnaire
was used to collect data on all cases and controls. Moreover,
family members, nurses, and family and/or primary-care
physicians were asked about drug exposures.
Finally, as with all case–control studies, we cannot
exclude confounding bias. As neurological disorders may
be strongly associated with chronic drug intake, we collected
extensive information on chronic drug exposures before BP
onset, which was allowed by the prospective recruitment of
case and control patients. In particular, control patients
matched with a hospitalized BP patient were recruited among
patients seen for an acute condition at the emergency
department of the same hospital to minimize any impact of
reason for admission on chronic drug exposure.
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In conclusion, degenerative neurological diseases, uni-
polar or bipolar disorder, being confined to bed, and chronic
use of neuroleptics or spironolactone are independent risk
factors for BP. These findings may have implications for the
management of BP patients. Moreover, they indicate a need
for further investigations into the association of BP with
neurological disorders.
MATERIALS AND METHODS
This case–control study with prospective recruitment was conducted
from January 2003 through April 2007 in 11 dermatology depart-
ments (11 hospitals) in France. We used a hospital-based design
because nearly all patients with BP in France are referred to hospital
dermatology departments.
Cases
Consecutive incident cases of BP were included. Cases were defined as
in-patients or outpatients with BP diagnosed within the last year. The
diagnosis of BP was based on typical clinical features (Vaillant et al.,
1998; Joly et al., 2004) and on direct immunofluorescence showing
linear deposits of IgG and/or C3 along the basement membrane zone.
The following clinical data were recorded: date of first cutaneous
symptoms (usually pruritic erythematous/urticarial lesions), number of
new blisters per day (determined over a 3-day period), peripheral
eosinophil count (giga cells per liter), and antibodies to the basement
membrane zone detected by indirect immunofluorescence.
Controls
Two control patients were individually matched to each case on
gender, age (within 5 years), place of residence (home, nursing home,
or extended-care geriatric facility), and center. Controls were recruited
among patients referred to an outpatient dermatology clinic for skin
tumors (melanoma, basal cell carcinoma, squamous cell carcinoma, or
benign tumors) and among patients admitted to the study hospitals for
acute conditions such as fractures and hip- or knee-joint-replacement
surgery that were a priori unrelated to chronic drug intake or
comorbidities. Among the 402 controls, 57 were admitted for a
chronic disorder and were secondarily excluded. Of the remaining 345
controls, 130 had malignant skin tumors, 49 benign skin tumors, and
166 acute conditions requiring hospital admission.
The study adhered to the Declaration of Helsinki Principles, and
was approved by the institutional review boards of Ile-de-France IX
(Paris, France). According to the French law on epidemiological
research, patients were informed and gave their oral consent.
Data collection
Cases and controls were interviewed to complete a standardized
questionnaire. When a patient was unable to answer, we inter-
viewed a family member or nurse. The questionnaire collected
demographic characteristics, place of residence (home, nursing
home, or extended-care geriatric facility), center, body mass index,
and comorbidities. Specific items existed for skin conditions
including past or current psoriasis, history of severe burns, pressure
sores, leg ulcers, or other chronic wounds, and history of radio-
therapy within the past 10 years. Information was collected on the
following nondermatological conditions: thyroid dysfunction, dia-
betes mellitus, neurological disorders (stroke, dementia, multiple
sclerosis, and Parkinson’s disease), mental disorders such as unipolar
and bipolar disorders, musculoskeletal disorders associated with
diminished self-sufficiency (history of fracture, joint-replacement
surgery, or chronic inflammatory joint disease such as rheumatoid
arthritis. The questionnaire also obtained information on chronic
drug intake. We hypothesized that several months of drug use were
required to induce BP and the questionnaire therefore collected data
only on drugs used for more than 3 months within the 6 months
preceding disease onset (or during the corresponding calendar
period in controls). In addition, information was obtained from
family members, nurses, and the family and/or primary-care
physician of each patient. Drugs were then classified into groups
according to the Anatomical Therapeutic Chemical Classification
System with defined daily doses.
Cases and controls were evaluated for cognitive impairment
using the MMSE. This brief 30-point questionnaire is commonly used
to screen for dementia. A score of 24–30 indicates no cognitive
impairment; 18–23, mild cognitive impairment; and 0–17, severe
cognitive impairment or dementia (Folstein et al., 1975). The Braden
scale was used to assess the patient’s level of risk for pressure ulcers.
This scale is based on six indicators: sensory perception, moisture,
activity, mobility, nutrition, and friction or shear. This summated
rating scale has six subscales scored from 1 to 3 or 4, and the total
score can range from 6 to 23. A lower Braden Scale Score indicates a
lower level of function and, therefore, a higher risk for pressure ulcer
development. A score o17 indicates that the patient is confined to
bed (Braden and Berstrom, 1990). Physical self-sufficiency was
assessed using the Barthel index, which consists of 10 items that
measure activities of daily living and mobility. The items include
feeding, moving from the wheelchair to the bed and vice versa,
grooming, transferring to and from a toilet, bathing, walking on a
level surface, going up and down stairs, dressing, and continence of
bowels and bladder. The scores for each of the items are summed to
yield the total score ranging from 0 to 100. Higher scores indicate
greater self-sufficiency and scores lower than 20 indicate depen-
dency (Khaoulani and Calmels, 1991).
Statistical analysis
With the a risk set at 0.05, 200 cases were needed to provide
80% power for detecting ORs 42 related to factors present in
5–15% of the control population and ORs 43 related to factors
present in 2–3% of the control population. We included 201 cases
and we identified 402 potential controls, among whom 345 were
included.
Tables 1 and 2 list the variables compared between cases and
controls. Qualitative variables, described as number (%), were
compared using the w2-test or Fisher exact test, as appropriate.
Quantitative variables, described as mean (SD) or median IQR) as
appropriate, were compared using the nonparametric Kruskal–Wallis
test. To estimate ORs, we dichotomized the quantitative variables
using previously published cutoffs: MMSE score,p17 or417 (Crum
et al., 1993); Braden scale score, o17 or X17 (Braden and
Berstrom, 1990); and Barthel index, o20 or X20 (Khaoulani and
Calmels, 1991). Data were analyzed using standard methods for
estimating ORs and 95% CIs in case–control studies. ORs were
estimated separately for each potential risk factor using uncondi-
tional logistic regression models, forcing the matching variables into
all models. Variables yielding P-values o0.15 in the univariate
analyses were considered for the multivariate analyses. First-order
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interactions and confounding factors were looked for using multiple
two-by-two analyses. Finally, a backward stepwise logistic regres-
sion analysis was performed.
To look for selection bias in the control population, we compared
the prevalence rates of factors significantly associated with BP across
control–patient categories (malignant skin tumors, benign skin
tumors, and acute disorders). All tests were two-tailed and P-values
no greater than 0.05 were considered significant. No adjustments for
multiple comparisons were performed. Data were analyzed using
STATA software version 8 and SE11 (Stata, College Station, TX).
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